{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T16:00:09Z","timestamp":1772121609806,"version":"3.50.1"},"reference-count":43,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","semarthritisrheumatism.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1016\/j.semarthrit.2015.01.006","type":"journal-article","created":{"date-parts":[[2015,1,23]],"date-time":"2015-01-23T02:19:30Z","timestamp":1421979570000},"page":"672-679","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Etanercept in refractory lupus arthritis: An observational study"],"prefix":"10.1016","volume":"44","author":[{"given":"Josefina","family":"Cort\u00e9s-Hern\u00e1ndez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"Egri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miquel","family":"Vilardell-Tarr\u00e9s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josep","family":"Ordi-Ros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2015.01.006_bib1","first-page":"1147","volume":"5","author":"Maddison","year":"1998"},{"key":"10.1016\/j.semarthrit.2015.01.006_bib2","series-title":"Dubois\u2019 lupus erythematosus","first-page":"635","author":"Wallace","year":"1997"},{"key":"10.1016\/j.semarthrit.2015.01.006_bib3","first-page":"777","article-title":"Arthropathy of hands and feet in systematic lupus erythematosus","volume":"17","author":"Reilly","year":"1990","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2015.01.006_bib4","first-page":"777","article-title":"Arthropathy of hands and feet in systemic lupus erythematosus","volume":"17","author":"Reilly","year":"1990","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2015.01.006_bib5","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/MD.0b013e3181632d18","article-title":"Jaccoud arthropathy in systemic lupus erythematosus: analysis of clinical characteristics and review of the literature","volume":"87","author":"Santiago","year":"2008","journal-title":"Medicine"},{"key":"10.1016\/j.semarthrit.2015.01.006_bib6","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1756-185X.2011.01665.x","article-title":"Efficacy and safety of methotrexate in articular and cutaneous manifestations of systemic lupus erythematosus","volume":"15","author":"Islam","year":"2012","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.semarthrit.2015.01.006_bib7","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1002\/art.24068","article-title":"Canadian network for improved outcomes in systemic lupus. Steroid-sparing effects of methotrexate in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial","volume":"59","author":"Fortin","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2015.01.006_bib8","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/art.25052","article-title":"Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial","volume":"62","author":"Ginzler","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2015.01.006_bib9","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1093\/rheumatology\/kep396","article-title":"The BILAG multi-centre open randomized controlled trial comparing ciclosporin vs azathioprine in patients with severe SLE","volume":"49","author":"Griffiths","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2015.01.006_bib10","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1191\/0961203304lu1067sr","article-title":"Double-blind randomized, placebo-controlled pilot study of leflunomide in systemic lupus erythematosus","volume":"13","author":"Tam","year":"2004","journal-title":"Lupus"},{"key":"10.1016\/j.semarthrit.2015.01.006_bib11","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1080\/03009740701607042","article-title":"Mycophenolate mofetil for non-renal manifestations of systemic lupus erythematosus: a systematic review","volume":"36","author":"Mok","year":"2007","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.semarthrit.2015.01.006_bib12","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1136\/ard.2006.067124","article-title":"B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response","volume":"66","author":"Ng","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2015.01.006_bib13","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S0140-6736(89)90430-3","article-title":"Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis","volume":"2","author":"Brennan","year":"1989","journal-title":"Lancet"},{"issue":"Suppl. 2","key":"10.1016\/j.semarthrit.2015.01.006_bib14","doi-asserted-by":"crossref","first-page":"ii2","DOI":"10.1136\/ard.62.suppl_2.ii2","article-title":"Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases","volume":"62","author":"Furst","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2015.01.006_bib15","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1136\/ard.2005.042630","article-title":"An international study on starting tumour necrosis factor-blocking agents in ankylosing spondylitis","volume":"65","author":"Pham","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2015.01.006_bib16","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2174\/1381612033391982","article-title":"Anti-TNF therapy for Crohn\u2019s disease","volume":"9","author":"D\u2019Haens","year":"2003","journal-title":"Curr Pharmacol Des"},{"key":"10.1016\/j.semarthrit.2015.01.006_bib17","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1002\/1529-0131(200011)43:11<2383::AID-ANR2>3.0.CO;2-D","article-title":"Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials","volume":"43","author":"Charles","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2015.01.006_bib18","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/MD.0b013e3181441a68","article-title":"Autoimmune diseases induced by TNF-targeted therapies analysis of 233 cases","volume":"86","author":"Ramos-Casals","year":"2007","journal-title":"Medicine"},{"key":"10.1016\/j.semarthrit.2015.01.006_bib19","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1093\/rheumatology\/kep080","article-title":"Anti-TNF-induced lupus","volume":"48","author":"Williams","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2015.01.006_bib20","first-page":"401","article-title":"Anti-nuclear antibodies, anti-DNA and C4 complement evolution in rheumatoid arthritis and ankylosing spondylitis with TNF-alpha blockers","volume":"26","author":"Gonnet-Garcia","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2015.01.006_bib21","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1093\/rheumatology\/35.11.1067","article-title":"Tumour necrosis factor alpha and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus","volume":"35","author":"Studnicka-Benke","year":"1996","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.semarthrit.2015.01.006_bib22","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1002\/art.1780360812","article-title":"Correlation between serum levels of soluble tumor necrosis factor receptor and disease activity in systemic lupus erythematosus","volume":"36","author":"Aderka","year":"1993","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2015.01.006_bib23","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/anr.1780320206","article-title":"Tumor necrosis factor in the serum of patients with systemic lupus erythematosus","volume":"32","author":"Maury","year":"1989","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2015.01.006_bib24","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1191\/0961203305lu2053oa","article-title":"Cytokine expression in lupus kidneys","volume":"14","author":"Aringer","year":"2005","journal-title":"Lupus"},{"key":"10.1016\/j.semarthrit.2015.01.006_bib25","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1002\/art.20576","article-title":"Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study","volume":"50","author":"Aringer","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2015.01.006_bib26","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1093\/rheumatology\/kep270","article-title":"Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients","volume":"48","author":"Aringer","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2015.01.006_bib27","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/art.22327","article-title":"Effect of short-term infliximab therapy on autoantibodies in systemic lupus erythematosus","volume":"56","author":"Aringer","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2015.01.006_bib28","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1056\/NEJM199707173370301","article-title":"Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor(p75)-Fc fusion protein","volume":"337","author":"Moreland","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2015.01.006_bib29","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1093\/rheumatology\/keh483","article-title":"Anti-TNF-a therapies: they are all the same (aren\u2019t they?)","volume":"44","author":"Mpofu","year":"2005","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2015.01.006_bib30","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.semarthrit.2005.01.005","article-title":"Tumor necrosis factor inhibitors: clinical implications of their different immunogenicity profiles","volume":"34","author":"Anderson","year":"2005","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2015.01.006_bib31","first-page":"s413","article-title":"Successful treatment of a patient suffering from a refractory subacute cutaneous lupus erythematosus (SCLE) with blocker of tumor necrosis factor alpha","volume":"50","author":"Hiepe","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2015.01.006_bib32","doi-asserted-by":"crossref","first-page":"308","DOI":"10.3109\/s10165-011-0500-1","article-title":"Etanercept for the treatment of intractable hemophagocytic syndrome with systemic lupus erythematosus","volume":"22","author":"Kikuchi","year":"2012","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.semarthrit.2015.01.006_bib33","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1002\/art.1780251101","article-title":"The 1982 revised criteria for the classification of systemic lupus erythematosus","volume":"25","author":"Tan","year":"1982","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2015.01.006_bib34","first-page":"288","article-title":"Systemic lupus erythematosus disease activity index 2000","volume":"29","author":"Gladman","year":"2002","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2015.01.006_bib35","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/art.1780390303","article-title":"The development and initial validation of the Systemic Lupus International Collaborating Clinics\/American College of Rheumatology damage index for systemic lupus erythematosus","volume":"39","author":"Gladman","year":"1996","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2015.01.006_bib36","first-page":"1321","article-title":"Anticardiolipin antibodies and dependence of a serum cofactor. A mechanism of thrombosis","volume":"20","author":"Ordi","year":"1993","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2015.01.006_bib37","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1055\/s-0038-1648143","article-title":"Guidelines for testing and revised criteria for lupus anticoagulants. SSC Subcommittee for the Standardization of Lupus Anticoagulants","volume":"65","author":"Exner","year":"1991","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.semarthrit.2015.01.006_bib38","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1002\/art.21190","article-title":"Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis","volume":"52","author":"De Rycke","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2015.01.006_bib39","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1177\/0961203309102557","article-title":"Efficacy and safety of infliximab in active SLE: a pilot study","volume":"18","author":"Uppal","year":"2009","journal-title":"Lupus"},{"key":"10.1016\/j.semarthrit.2015.01.006_bib40","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/S0140-6736(12)61811-X","article-title":"Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial","volume":"381","author":"Smolen","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2015.01.006_bib41","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1136\/ard.2007.087411","article-title":"Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register","volume":"68","author":"Prince","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2015.01.006_bib42","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/s10067-006-0219-0","article-title":"Safety and Efficacy of infliximab in a patient with active WHO class IV nephritis","volume":"26","author":"Hayat","year":"2007","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2015.01.006_bib43","first-page":"416","article-title":"Anti-tumor necrosis factor therapy in patients with difficult to treat lupus nephritis: a prospective series of nine patients","volume":"27","author":"Matsumura","year":"2009","journal-title":"Clin Exp Rheumatol"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017215000074?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017215000074?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T10:05:25Z","timestamp":1747476325000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017215000074"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["S0049017215000074"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2015.01.006","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725514687.793506997","asserted-by":"object"}]},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Etanercept in refractory lupus arthritis: An observational study","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2015.01.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}